Stanley Plotkin, MD, Discusses Scientific Progress and the Complexities of Public Health Vaccine Policy
Article Sidebar
Main Article Content
Abstract
Stanley Plotkin, M.D., reflects on his professional journey, describing how formative educational experiences influenced his career. He discusses his contributions to vaccine development, notably for rubella and rotavirus, and shares insight on advancements in vaccine technology, including strengths and limitations of mRNA and DNA platforms. Dr. Plotkin emphasizes the importance of adapting public health recommendations as scientific understanding evolves, discusses the challenges of establishing mucosal immunity, and highlights the benefits of combining vaccines. He also offers thoughtful perspectives on natural versus vaccine-induced immunity, drawing upon his extensive expertise. Finally, he touches on his personal interest in learning to fly.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. Walter A. Orenstein, Offit PA, Edwards KM, Plotkin SA. Plotkin’s Vaccines. 8 ed: Elsevier; 2024.
2. De Kruif P. Microbe Hunters: Harcourt, Brace and Company, Inc.; 1926.
3. Lewis S. Arrowsmith: Harcourt, Brace and Company, Inc.; 1925.
4. Plotkin SA, Robinson JM, Fitchett JRA, Gershburg E. Vaccine Development Should Be Polytheistic, Not Monotheistic. Clin Infect Dis. 2024;79(6):1518-20. doi: 10.1093/cid/ciae460. PubMed PMID: 39240717.
5. Saville M, Cramer JP, Downham M, Hacker A, Lurie N, Van der Veken L, Whelan M, Hatchett R. Delivering Pandemic Vaccines in 100 Days - What Will It Take? N Engl J Med. 2022;387(2):e3. doi: 10.1056/NEJMp2202669. PubMed PMID: 35249271.
6. Plotkin SA, Mahmoud AA, Farrar J. Establishing a Global Vaccine-Development Fund. N Engl J Med. 2015;373(4):297-300. doi: 10.1056/NEJMp1506820. PubMed PMID: 26200974.
7. Bousbaine D, Bauman KD, Chen YE, Lalgudi PV, Nguyen TTD, Swenson JM, Yu VK, Tsang E, Conlan S, Li DB, Jbara A, Zhao A, Naziripour A, Veinbachs A, Lee YE, Phung JL, Dimas A, Jain S, Meng X, Pham TPT, McLaughlin MI, Barkal LJ, Gribonika I, Van Rompay KKA, Kong HH, Segre JA, Belkaid Y, Barnes CO, Fischbach MA. Discovery and engineering of the antibody response to a prominent skin commensal. Nature. 2025;638(8052):1054-64. doi: 10.1038/s41586-024-08489-4. PubMed PMID: 39662508; PMCID: PMC12045117.